Likewise, our in vitro assessment of volasertib sensitivity across a panel of primary AML samples from patients cared for at our institution demonstrated that increased mutational burden of the FA pathway is associated with greater sensitivity to PLK1 inhibition. Here, PLK1 is linked to acute myeloid leukemia.